Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1103]

Radiation therapy after radical surgery in prostate cancer

Dr Roberto Paz - Oncosalud - AUNA, Lima, Peru

Radiation therapy after radical surgery in prostate cancer ( Dr Roberto Paz - Oncosalud - AUNA, Lima, Peru )

iCCaRE Consortium for Black Men: Second Discussion

Mr Arnold Merriweather, Dr Che Ngufor and Dr Folakemi Odedina

iCCaRE Consortium for Black Men: Second Discussion ( Mr Arnold Merriweather, Dr Che Ngufor and Dr Folakemi Odedina )

ASCO 2023: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2023: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

ASCO 2023: Latest in PARP inhibitors in prostate cancer

Prof Rana McKay, Dr Friederike Schlurmann, Prof Gunhild von Amsberg

ASCO 2023: Latest in PARP inhibitors in prostate cancer ( Prof Rana McKay, Dr Friederike Schlurmann, Prof Gunhild von Amsberg )

Talazoparib plus enzalutamide shows improvement in PFS over standard of care in...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Talazoparib plus enzalutamide shows improvement in PFS over standard of care in firstline HRR mCRPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

Extended lymph node removal does not benefit patients with clinically localised...

Dr Seth Lerner - Baylor College of Medicine, Houston, USA

Extended lymph node removal does not benefit patients with clinically localised muscle-invasive bladder cancer ( Dr Seth Lerner - Baylor College of Medicine, Houston, USA )

Trastuzumab deruxtecan gives strong anti-tumour activity and durable responses...

Dr Funda Meric-Bernstram - MD Anderson Cancer Center, Houston, USA

Trastuzumab deruxtecan gives strong anti-tumour activity and durable responses in multiple tumour types ( Dr Funda Meric-Bernstram - MD Anderson Cancer Center, Houston, USA )

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

ASCO 2023: Latest in mRCC

Dr Javier Puente, Dr Cristina Suárez, Prof Stéphane Oudard, Prof Viktor Grünwald

ASCO 2023: Latest in mRCC ( Dr Javier Puente, Dr Cristina Suárez, Prof Stéphane Oudard, Prof Viktor Grünwald )

Erdafitinib and current treatment landscape for advanced bladder cancer

Dr Yohann Loriot and Prof Arlene Siefker-Radtke

Erdafitinib and current treatment landscape for advanced bladder cancer ( Dr Yohann Loriot and Prof Arlene Siefker-Radtke )

AI-derived digital pathology-based biomarker predicts benefit of long-term ADT...

Prof Andrew Armstrong - Duke University, Durham, USA

AI-derived digital pathology-based biomarker predicts benefit of long-term ADT with RT in localised high-risk prostate cancer ( Prof Andrew Armstrong - Duke University, Durham, USA )

Tackling low-volumes of clinical trials in Africa

Prof Ifeoma Okoye - University of Nigeria, Nsukka, Nigeria

Tackling low-volumes of clinical trials in Africa ( Prof Ifeoma Okoye - University of Nigeria, Nsukka, Nigeria )

More from ecancer